To page body
university of tampere: faculty of medicine and life sciences: research: research groups:
Faculty of Medicine and Life SciencesUniversity of TampereFaculty of Medicine and Life Sciences

Surgery

Professor (Urology):
Teuvo Tammela
tel. +358 (0)40 190 1489
teuvo.tammela@uta.fi

Professor (Surgery, especially Orthopaedics and Traumatology, Seinäjoki):
Harri Pihlajamäki
harri.pihlajamaki@epshp.fi

Professor (Cardiac Surgery):
Jari Laurikka
tel. +358 (0)3 3116 7669
jari.laurikka@sydankeskus.fi

Associate professor (Blood Vessel Surgery):
Niku Oksala
niku.oksala@uta.fi

Clinical teachers:
Heidi Haapasalo (Orthopaedics and Traumatology), e-mail: heidi.haapasalo@uta.fi
Margit Karelson (Arm Surgery), e-mail: margit.karelson@uta.fi
Kirsi Lehto (Gastroenterology), e-mail: kirsi.m.lehto@uta.fi
Teemu Murtola (Urology), e-mail: teemu.murtola@uta.fi
Timo Halonen (Plastic Surgery), Seinäjoki, e-mail: timo.halonen@epshp.fi


Laboratory of Regenerative Medicine >>

Surgery (Cardiac Surgery) >>

Urology >>


Recent publications:

Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, Tammela TL, Auvinen A
Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Int J Urol ;2017
PMID

Eskelinen TJ, Kotsar A, Tammela TLJ, Murtola TJ
Components of metabolic syndrome and prognosis of renal cell cancer.
Scand J Urol ;51(6)435-441, 2017
PMID

Tammela TL, Häggman M, Ladjevardi S, Taari K, Isotalo T, Lennernäs H, Weis J, von Below C, Wassberg C, Lennernäs B, Tolf A, Axén N, Gölander CG, Ahlström H
An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
J Urol ;198(6)1333-1339, 2017
PMID

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS
Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.
Am J Surg Pathol ;2017
PMID

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
Eur Urol Focus ;2017
PMID

Kallio J, Hämäläinen M, Luukkaala T, Moilanen E, Tammela TL, Kellokumpu-Lehtinen PL
Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer.
Urol Oncol ;35(9)544.e25-544.e31, 2017
PMID

Saarimäki L, Hugosson J, Tammela TL, Carlsson S, Talala K, Auvinen A
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Eur Urol Focus ;2017
PMID

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J
A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Prostate ;77(11)1213-1220, 2017
PMID

Kilpeläinen TP, Pogodin-Hannolainen D, Kemppainen K, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, Auvinen A
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.
J Urol ;198(1)50-57, 2017
PMID

Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A
Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
BMC Cancer ;17(1)585, 2017
PMID

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
Cell Rep ;19(10)2045-2059, 2017
PMID

Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ
The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.
Prostate ;77(9)1029-1035, 2017
PMID

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Oksala N, Pettersson K, Tammela TL
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Eur J Epidemiol ;32(6)521-527, 2017
PMID

Lehto US, Aromaa A, Tammela TL
Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment.
Eur J Cancer Care (Engl) ;2017
PMID

Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A
Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Eur Urol Focus ;3(2-3)212-220, 2017
PMID

Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.
Eur Urol Focus ;2017
PMID

Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Eur Urol Focus ;2017
PMID

Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TLJ, Auvinen A
Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
J Urol ;2017
PMID

Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Scand J Urol ;51(1)5-12, 2017
PMID

Murtola TJ, Vettenranta AM, Talala K, Taari K, Stenman UH, Tammela TLJ, Auvinen A
Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Eur Urol Focus ;2017
PMID

Nevalainen J, Stenman UH, Tammela TL, Roobol M, Carlsson S, Talala K, Schröder FH, Auvinen A
What explains the differences between centres in the European screening trial? A simulation study.
Cancer Epidemiol ;2017
PMID

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Eur Urol ;71(2)151-154, 2017
PMID

Syvälä H, Pennanen P, Bläuer M, Tammela TL, Murtola TJ
Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.
Biochem Biophys Res Commun ;481(1-2)46-50, 2016
PMID

Joentausta RM, Kujala PM, Visakorpi T, Tammela TL, Murtola TJ
Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Prostate Cancer Prostatic Dis ;19(4)367-373, 2016
PMID

Kaapu KJ, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A
Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Br J Cancer ;115(11)1289-1295, 2016
PMID

Pennanen P, Syvälä H, Bläuer M, Savinainen K, Ylikomi T, Tammela TLJ, Murtola TJ
The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.
Eur J Pharmacol ;2016
PMID

Pakarainen T, Raitanen J, Talala K, Taari K, Kujala P, Tammela TL, Auvinen A
Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
Eur Urol ;70(3)499-505, 2016
PMID

Kinnunen PT, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A
Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Scand J Urol ;50(6)413-419, 2016
PMID

Kilpeläinen TP, Mäkinen T, Karhunen PJ, Aro J, Lahtela J, Taari K, Talala K, Tammela TL, Auvinen A
Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer.
Cancer Epidemiol ;2016
PMID

Nurminen R, Rantapero T, Wong SC, Fischer D, Lehtonen R, Tammela TL, Nykter M, Visakorpi T, Wahlfors T, Schleutker J
Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
Genes Chromosomes Cancer ;55(8)661-73, 2016
PMID

Sarre S, Määttänen L, Tammela TL, Auvinen A, Murtola TJ
Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
Scand J Urol ;50(4)267-73, 2016
PMID

Pesonen JS, Cartwright R, Mangera A, Santti H, Griebling TL, Pryalukhin AE, Riikonen J, Tähtinen RM, Agarwal A, Tsui JF, Vaughan CP, Markland AD, Johnson TM, Fonsell-Annala R, Khoo C, Tammela TL, Aoki Y, Auvinen A, Heels-Ansdell D, Guyatt GH, Tikkinen KA
Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis.
Eur Urol ;70(2)372-81, 2016
PMID

Kilpeläinen TP, Talala K, Raitanen J, Taari K, Kujala P, Tammela TL, Auvinen A
Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer.
Am J Epidemiol ;2016
PMID

Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A
Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Eur Urol Focus ;2016
PMID

Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A
5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Int J Cancer ;138(12)2820-8, 2016
PMID

Pöyhönen A, Auvinen A, Häkkinen JT, Koskimäki J, Tammela TL
Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men.
Urology ;2016
PMID

Salminen JK, Tammela TL, Auvinen A, Murtola TJ
Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study.
Cancer Causes Control ;27(5)637-45, 2016
PMID

Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, Vuorela A, Nykänen P, Pohjanjousi P, Snapir A, Fizazi K
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.
Eur Urol ;69(5)834-40, 2016
PMID

Latonen L, Leinonen KA, Grönlund T, Vessella RL, Tammela TL, Saramäki OR, Visakorpi T
Amplification of the 9p13.3 chromosomal region in prostate cancer.
Genes Chromosomes Cancer ;55(8)617-25, 2016
PMID

Keskiväli T, Kujala P, Visakorpi T, Tammela TL, Murtola TJ
Statin use and risk of disease recurrence and death after radical prostatectomy.
Prostate ;76(5)469-78, 2016
PMID

Laitinen VH, Akinrinade O, Rantapero T, Tammela TL, Wahlfors T, Schleutker J
Germline copy number variation analysis in Finnish families with hereditary prostate cancer.
Prostate ;76(3)316-24, 2016
PMID

Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Eur Urol ;69(4)720-7, 2016
PMID

Sjöblom L, Saramäki O, Annala M, Leinonen K, Nättinen J, Tolonen T, Wahlfors T, Nykter M, Bova GS, Schleutker J, Tammela TL, Lilja H, Visakorpi T
Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
PLoS One ;11(3)e0150241, 2016
PMID

Kaapu KJ, Murtola TJ, Määttänen L, Talala K, Taari K, Tammela TL, Auvinen A
Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Cancer Causes Control ;27(2)157-64, 2016
PMID

Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
Clin Cancer Res ;22(1)243-9, 2016
PMID

 
Maintained by: med.info@uta.fi
Last update: 4.1.2017 15.15 Muokkaa

University of Tampere
+358 3 355 111
registry@uta.fi


FINEEC Audited HR Excellence in Research

THE UNIVERSITY
Research
Admissions
Studies
News
Cooperation and Services
About Us

CURRENT ISSUES
Research & Study
Tampere3
Vacancies

SERVICES
Administration
Career Services
Finnish Social Science Data Archive
Centre for International Education
IT services
Language Centre
Language Services
Library
Registrar's Office
Registry
Sports Activities
» more

STUDIES
Teaching schedules
Curricula guides
Student's Desktop

ONLINE SERVICES
Andor search
Renew your loans
UTA intranet
Office 365 webmail
Uta webmail
Moodle
NettiOpsu
NettiKatti
TamPub
Electronic exam service
Examination results